ok, here is a link: http://www.allbusiness.com/company-activities-management/fin...
From the same book quoted above, in 1990 it was roughly 1:3.2, since then the situation has improved a bit, but I can't find anything closer than 2004.
Still, it is quite shocking when you realize that most of the marketing goes towards pushing a few, well established drugs at immense markups, and that most research is focused on either extending the life of these drugs or the introduction of replacement drugs for drugs that are on their last legs in the patent cycle.
Genuine research (research which attacks problems for which no current solution exists) is a very very small fraction of total expenditure.
more interesting data here: (not sure if that link works...)